Download PDF
Der Klinikarzt 2019; 48(06): 242-249
DOI: 10.1055/a-0957-2642
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Diagnostik und Therapie des Pankreaskarzinoms

Neue Ansätze bei einem aggressiven Krankheitsbild
Ihsan Ekin Demir
1   Klinik und Poliklinik für Chirurgie, Klinikum rechts der Isar, Technische Universität München
,
Christoph Schlag
2   II Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München
,
Rami Abbassi
2   II Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München
,
Hana Algül
2   II Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München
,
Rickmer Braren
3   Institut für diagnostische und interventionelle Radiologie, Klinikum rechts der Isar, Technische Universität München
,
Güralp O. Ceyhan
1   Klinik und Poliklinik für Chirurgie, Klinikum rechts der Isar, Technische Universität München
› Author Affiliations
Further Information

Publication History

Publication Date:
17 July 2019 (online)

Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Das Pankreaskarzinom weist eine weltweit steigende Inzidenz auf, wobei die Gründe hierfür bis dato nicht bekannt sind. Die NCCN-Leitlinie von 2017 empfiehlt zur Diagnose und Beurteilung der Resektabilität des pankreatischen duktalen Adenokarzinoms (PDAC) die Computertomografie (CT) als primäre Bildgebung. Bei fehlendem Nachweis und Verdacht eines Tumors wird die Magnetresonanztomografie (MRT) zur Abklärung kleiner Tumoren sowie zur Diagnostik einer eventuellen Lebermetastasierung empfohlen. Durch den Einsatz von neoadjuvanten Chemotherapieregimes konnte die Anzahl der insgesamt resezierbaren Tumoren deutlich gesteigert und somit auch die Prognose dramatisch verbessert werden. Inzwischen sind neue Therapiekonzepte etabliert, die zu einer signifikanten Verbesserung der Prognose beim inoperablen Pankreaskarzinom in der palliativen Situation geführt haben. Im Rahmen der Erkrankung mit einem Pankreaskarzinom kann es zu einer Verlegung der Gallenwege und konsekutiv zu Cholestase und Cholangitis kommen. In einem solchen Fall sollte, sofern möglich, der Galleabfluss wiederhergestellt werden. Eine adäquate Therapieoption stellt hierbei die Durchführung einer ERCP mit Stentanlage dar. Auch bei Obstruktion des Duodenums ist eine endoskopische Stentanlage zur Wiederherstellung der Passage eine Option.

 

  • Literatur

  • 1 Iglesias-Garcia J, Lindkvist B, Larino-Noia J. et al. Differential diagnosis of solid pancreatic masses: contrast-enhanced harmonic (CEH-EUS), quantitative-elastography (QE-EUS), or both?. United European Gastroenterol 2017; 5: 236-246
    PubMedGoogle Scholar
  • 2 Puli SR, Singh S, Hagedorn CH. et al. Diagnostic accuracy of EUS for vascular invasion in pancreatic and periampullary cancers: a meta-analysis and systematic review. Gastrointest Endosc 2007; 65: 788-797
    CrossrefPubMedGoogle Scholar
  • 3 Chen J, Yang R, Lu Y. et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration for solid pancreatic lesion: a systematic review. J Cancer Res Clin Oncol 2012; 138: 1433-1441
    CrossrefPubMedGoogle Scholar
  • 4 Lidsky ME, Sun Z, Nussbaum DP. et al. Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers. Ann Surg 2016; 266: 333-338
    PubMedGoogle Scholar
  • 5 Dasari BV, Pasquali S, Vohra RS. et al. Extended Versus Standard Lymphadenectomy for Pancreatic Head Cancer: Meta-Analysis of Randomized Controlled Trials. J Gastrointest Surg 2015; 19: 1725-1732
    CrossrefPubMedGoogle Scholar
  • 6 Fang JZ, Lu CD, Wu SD. et al. Portal vein/superior mesenteric vein resection in pancreatic cancer treatment in the elderly. Medicine (Baltimore) 2017; 96: e7335
    PubMedGoogle Scholar
  • 7 Jegatheeswaran S, Baltatzis M, Jamdar S. et al. Superior mesenteric artery (SMA) resection during pancreatectomy for malignant disease of the pancreas: a systematic review. HPB (Oxford) 2017; 19: 483-490
    CrossrefPubMedGoogle Scholar
  • 8 Lahat G, Sever R, Lubezky N. et al. Pancreatic cancer: surgery is a feasible therapeutic option for elderly patients. World J Surg Oncol 2011; 9: 10
    CrossrefPubMedGoogle Scholar
  • 9 Petrucciani N, Debs T, Nigri G. et al. Pancreatectomy combined with multivisceral resection for pancreatic malignancies: is it justified? Results of a systematic review. HPB (Oxford) 2018; 20: 3-10
    CrossrefPubMedGoogle Scholar
  • 10 Verbeke C, Lohr M, Karlsson JS. et al. Pathology reporting of pancreatic cancer following neoadjuvant therapy: challenges and uncertainties. Cancer Treat Rev 2015; 41: 17-26
    CrossrefPubMedGoogle Scholar
  • 11 Ferrone CR, Marchegiani G, Hong TS. et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015; 261: 12-17
    CrossrefPubMedGoogle Scholar
  • 12 Oettle H, Post S, Neuhaus P. et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 2007; 297: 267-277
    CrossrefPubMedGoogle Scholar
  • 13 Neoptolemos JP, Palmer DH, Ghaneh P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389: 1011-1024
    CrossrefPubMedGoogle Scholar
  • 14 Conroy T, Hammel P, Hebbar M. et al. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. 2018. ASCO. Abstract #: LBA 4001
    Google Scholar
  • 15 Ueno H, Ioka T, Ikeda M. et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013; 31: 1640-1648
    CrossrefPubMedGoogle Scholar
  • 16 Uesaka K, Boku N, Fukutomi A. et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 2016; 388: 248-257
    CrossrefPubMedGoogle Scholar
  • 17 Janssen QP, Buettner S, Suker M. et al. Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis. 2018. ASCO. Abstract #: c16207
    Google Scholar
  • 18 Dhir M, Zenati MS, Hamad A. et al. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. Ann Surg Oncol 2018; 25: 1896-1903
    CrossrefPubMedGoogle Scholar
  • 19 Okada KI, Hirono S, Kawai M. et al. Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer. Anticancer Res 2017; 37: 853-858
    PubMedGoogle Scholar
  • 20 Schwarz L, Vernerey D, Bachet JB. et al. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy – a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer 2018; 18: 762
    CrossrefPubMedGoogle Scholar
  • 21 Turner K, Narayanan S, Attwood K. et al. Neoadjuvant FOLFIRINOX and/or gemcitabine/nab-paclitaxel for advanced pancreatic adenocarcinoma. J Clin Oncol 2017; 35: 473
    PubMedGoogle Scholar
  • 22 Mokdad AA, Minter RM, Zhu H. et al. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. J Clin Oncol 2017; 35: 515-522
    PubMedGoogle Scholar
  • 23 Gillen S, Schuster T, Meyer Zum Buschenfelde C. et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7: e1000267
    CrossrefPubMedGoogle Scholar
  • 24 Kunzmann V, Martens UM, Alguel H. et al. Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP). 2018. ASCO. Abstract #: 348
    Google Scholar
  • 25 Stirrups R. Chemoradiotherapy for pancreatic adenocarcinoma. Lancet Oncol 2018. DOI: https://doi.org/10.1016/S1470-2045(18)30358-9
    CrossrefGoogle Scholar
  • 26 Conroy T, Desseigne F, Ychou M. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825
    CrossrefPubMedGoogle Scholar
  • 27 Von Hoff DD, Ervin T, Arena FP. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-703
    CrossrefPubMedGoogle Scholar
  • 28 Dahan L, Phelip JM, Malicot KL. et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35- PANOPTIMOX). ASCO 2018. Abstract # 4000
    Google Scholar
  • 29 Portal A, Pernot S, Tougeron D. et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer 2015; 113: 989-995
    CrossrefPubMedGoogle Scholar
  • 30 Haas M, Siveke JT, Schenk M. et al. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‚Arbeitsgemeinschaft Internistische Onkologie’. Eur J Cancer 2017; 94: 95-103
    PubMedGoogle Scholar
  • 31 Moore MJ, Goldstein D, Hamm J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966
    CrossrefPubMedGoogle Scholar
  • 32 Pelzer U, Schwaner I, Stieler J. et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47: 1676-1681
    CrossrefPubMedGoogle Scholar
  • 33 Wang-Gillam A, Li CP, Bodoky G. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016; 387: 545-557
    CrossrefPubMedGoogle Scholar
  • 34 Gebbia V, Maiello E, Giuliani F. et al. Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol 2010; 33: 461-464
    CrossrefPubMedGoogle Scholar
  • 35 Zaniboni A, Aitini E, Barni S. et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol 2012; 69: 1641-1645
    CrossrefPubMedGoogle Scholar
  • 36 Toki MI, Syrigos KN, Saif MW. The role of biliary drainage in patients with pancreatic adenocarcinoma. Jop 2014; 15: 128-131
    PubMedGoogle Scholar
  • 37 Grimm IS, Baron TH. Biliary Stents for Palliation of Obstructive Jaundice: Choosing the Superior Endoscopic Management Strategy. Gastroenterology 2015; 149: 20-22
    CrossrefPubMedGoogle Scholar
  • 38 Baron TH, Grimm IS. Relief of obstructive jaundice from pancreatic cancer: the end of the plastic stent era?. Gut 2016; 65: 191-192
    CrossrefPubMedGoogle Scholar
  • 39 Tol JA, van Hooft JE, Timmer R. et al. Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer. Gut 2015; 65: 1981-1987
    PubMedGoogle Scholar
  • 40 Adams MA, Anderson MA, Myles JD. et al. Self-expanding metal stents (SEMS) provide superior outcomes compared to plastic stents for pancreatic cancer patients undergoing neoadjuvant therapy. J Gastrointest Oncol 2012; 3: 309-313
    PubMedGoogle Scholar
  • 41 Watanapa P, Williamson RC. Surgical palliation for pancreatic cancer: developments during the past two decades. Br J Surg 1992; 79: 8-20
    CrossrefPubMedGoogle Scholar
  • 42 Shah A, Fehmi A, Savides TJ. Increased rates of duodenal obstruction in pancreatic cancer patients receiving modern medical management. Dig Dis Sci 2014; 59: 2294-2298
    CrossrefPubMedGoogle Scholar
  • 43 Hosono S, Ohtani H, Arimoto Y. et al. Endoscopic stenting versus surgical gastroenterostomy for palliation of malignant gastroduodenal obstruction: a meta-analysis. J Gastroenterol 2007; 42: 283-290
    CrossrefPubMedGoogle Scholar